logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11208415 B1

PDFFull Text
Date of Patent:
Dec. 28, 2021

Filed:

Nov. 19, 2019

Substituted indole mcl-1 inhibitors

Applicant:

Vanderbilt University, Nashville, TN (US);

Inventors:

Taekyu Lee, Brentwood, TN (US);

Zhiguo Bian, Lake Bluff, IL (US);

Johannes Belmar, Nashville, TN (US);

Plamen P. Christov, Mount Juliet, TN (US);

Nicholas F. Pelz, Nashville, TN (US);

Subrata Shaw, Nashville, TN (US);

Kwangho Kim, Nashville, TN (US);

James C. Tarr, Franklin, TN (US);

Edward T. Olejniczak, Nashville, TN (US);

Bin Zhao, Brentwood, TN (US);

Stephen W. Fesik, Nashville, TN (US);

Assignee:

Vanderbilt University, Nashville, TN (US);

Attorney:

Michael Best & Friedrich LLP

Primary Examiner:

Shawquia Jackson

Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 209/42 (2006.01); A61K 31/551 (2006.01); A61K 31/381 (2006.01); A61K 31/4045 (2006.01); A61K 31/498 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); C07D 409/12 (2006.01); A61K 31/404 (2006.01); A61K 31/4155 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/4155 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); A61K 31/5377 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); C07D 209/42 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 471/04 (2013.01);
Abstract

The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

Find Patent Forward Citations

Loading…